STOCK TITAN

Adlai Nortye Ltd. American Depositary Shares - $ANL STOCK NEWS

Welcome to our dedicated page for Adlai Nortye Ltd. American Depositary Shares news (Ticker: $ANL), a resource for investors and traders seeking the latest updates and insights on Adlai Nortye Ltd. American Depositary Shares stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Adlai Nortye Ltd. American Depositary Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Adlai Nortye Ltd. American Depositary Shares's position in the market.

Rhea-AI Summary
Adlai Nortye appoints Dr. Archie Tse as Head of Research & Development, bringing extensive experience in oncology drug development to drive innovative cancer therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Summary
Adlai Nortye Ltd. (NASDAQ: ANL) announced the Completion of Patient Enrollment in Global Phase III Clinical Trial (BURAN) of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC in more than 180 sites around the world. This represents the first global multicenter phase III trial for HNSCC in the class of PI3K inhibitors, addressing the high unmet medical need for patients with recurrent or metastatic HNSCC after anti-PD-1/anti-PD-L1 therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.81%
Tags
-
Rhea-AI Summary
Adlai Nortye and Nucleai receive ESMO 2023 Best Poster Award for study on predicting response to Buparlisib in SCCHN
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.84%
Tags
none
Rhea-AI Summary
Adlai Nortye closes IPO, raising $57.5M from public offering and $40M from private placement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.87%
Tags
-
Rhea-AI Summary
Adlai Nortye announces pricing of IPO at $23.00 per ADS, expecting gross proceeds of $97.5 million
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Adlai Nortye Ltd. American Depositary Shares

Nasdaq:ANL

ANL Rankings

ANL Stock Data

497.42M
19.37M
6.96%
0.2%
0.02%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
Grand Cayman